Amendment to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

- 1-33. (Canceled)
- 34. (Currently amended) A composition comprising:

dead *E. coli* comprising at least one modified allergen whose amino acid sequence <u>is</u> identical to that of differs from that of a wild-type allergen that occurs in nature, except that the modified allergen has at least one mutation in an IgE site such that the modified allergen has a reduced ability to bind to or cross-link IgE as compared with the wild-type allergen, wherein the modified allergen is encapsulated inside the dead *E. coli*; and

- a pharmaceutically acceptable carrier.
- 35. (Original) The composition of claim 34, wherein the wild-type allergen is found in nature in foods, venoms, or latex.
- 36. (Original) The composition of claim 34, wherein the wild-type allergen is found in nature in a food selected from the group consisting of peanuts, milk, eggs, seafood, nuts, dairy products, and fruit.
- 37. (Withdrawn) The composition of claim 34, wherein the wild-type allergen is found in nature in bee venom.
- 38. (Previously presented) The composition of claim 34, wherein the wild-type allergen is an Ara h 1, Ara h 2, or Ara h 3 protein with an amino acid sequence that is encoded by the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
- 39. (Currently amended) The composition of claim 34, wherein the sequence of the modified allergen differs from the sequence of the wild-type allergen by one or more amino acid deletions, substitutions or additions within an IgE binding site of the wild-type peanut allergen.

Attorney's Docket No.: 2006517-0010

- 40. (Previously presented) The composition of claim 39, wherein the sequence of the modified allergen lacks an IgE binding site of the wild-type allergen sequence.
- 41. (Original) The composition of claim 34, wherein the modified allergen is located in the cytoplasm of the dead *E. coli*.
- 42. (Original) The composition of claim 34, wherein the modified allergen is located in the periplasm of the dead *E. coli*.
- 43. (Original) The composition of claim 34, wherein the modified allergen cannot be detected by antibody binding without disrupting the dead *E. coli*.
- 44. (Original) The composition of claim 34, wherein the composition is formulated for rectal administration.
- 45. (Previously presented) The composition of claim 34, wherein the dead *E. coli* was heat-killed.
- 46. (Previously presented) The composition of claim 34, wherein the dead *E. coli* was killed by chemical treatment.
- 47. (Previously presented) The composition of claim 44, wherein the dead *E. coli* was killed using a chemical selected from the group consisting of iodine, bleach, ozone, and alcohol.
- 48. (New) The composition of claim 34, wherein the composition is formulated for mucosal administration.
- 49. (New) The composition of claim 34, wherein the composition is formulated for oral administration.

Attorney's Docket No.: 2006517-0010